NCT00697814

Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Federal University of São Paulo · Academic / Other
• Sex: Male
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open label clinical trial of CC to evaluate its effects in reverting persistent HH in male patients with prolactinomas under dopaminergic agonist treatment.

Conditions

• Hypogonadotropic Hypogonadism
• Prolactinoma

Interventions

Type	Name	Description
DRUG	Clomiphene citrate	Clomiphene 50 mg/day for 12 weeks

Timeline

• Start date: 2004-06-01
• Primary completion: 2005-06-01
• Completion: 2005-06-01
• First posted: 2008-06-16
• Last updated: 2008-06-16

Locations

1 site across 1 country: Brazil